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Oesophageal squamous cell carcinoma is one of the most malignant tumours. To identify patients with a high risk of
recurrence of oesophageal squamous cell carcinoma, we investigated the prognostic signiﬁcance of survivin mRNA expression
in oesophageal squamous cell carcinoma, which has recently been reported to be a good marker for unfavourable prognosis
in various tumours. Tumours and non-cancerous epitheliums adjacent to tumours were obtained by surgical resection from 57
patients with oesophageal squamous cell carcinoma. Expression levels of survivin and glyceraldehyde-3-phosphate dehydrogenase
mRNA were analysed quantitatively by real-time reverse transcriptase polymerase chain reaction (RT–PCR). The survivin/
glyceraldehyde-3-phosphate dehydrogenase ratios of tumours were higher than those of non-cancerous tissues (P=0.0003).
Tumour-survivin/glyceraldehyde-3-phosphate dehydrogenase ratio did not correlate with histologic type, lymph node metastasis,
and stage of tumours. In 53 surviving patients, the 5-year survival rate of 17 patients with high survivin mRNA expressed
oesophageal squamous cell carcinoma (14.1%) was signiﬁcantly poorer than that of 36 with low survivin mRNA expressed
oesophageal squamous cell carcinoma (46.8%, P=0.0018). In these patients, tumour-survivin mRNA expression was recognised
as a good marker of cancer recurrence independently from tumour stage. These ﬁndings indicate that survivin mRNA
expression in oesophageal squamous cell carcinoma may be a good biomarker for identifying patients with high risk of cancer
recurrence.
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Oesophageal squamous cell carcinoma (OSCC) is one of the most
malignant tumours having a dismal prognosis. Lymph node metas-
tasis has a strong prognostic impact for patients with OSCC
(Tachibana et al, 1999; Hosch et al, 2001). However, even in early
stage OSCC, many patients develop recurrent tumours that once
developed indicate a poor patient prognosis. Starting adequate
adjuvant chemo-radiotherapy for patients with a high risk of
cancer recurrence is required. In order to identify patients with a
high risk of cancer recurrence, a variety of biologic markers have
been investigated (Sarbia et al, 1999; Ikeguchi et al, 2000).
However, these factors have not yet been sufﬁciently deﬁned in
patients with a high risk of cancer recurrence.
Several apoptosis inhibitors related to the baculovirus inhibitor
of apoptosis (IAP) genes have recently been identiﬁed in human
(Clem and Miller, 1994). Survivin belongs to a family of IAPs
and has been shown to bind and inhibit the cell-death terminal
effectors caspases-3 and -7, which induce apoptosis in cells
(Mahotka et al, 1999). Strong survivin expression has been
reported in several foetal tissues, whereas in adult tissues survivin
transcripts have been detected only in the thymus and placenta.
However, in the most common human cancers, survivin expression
is again turned on (Adida et al, 1998). Recently, the clinical impor-
tance of survivin messenger RNA (mRNA) expression has been
reported in various cancers including OSCC (Monzo ￿ et al, 1999;
Sarela et al, 2000; Kato et al, 2001). However, these reports were
based on the traditional reverse transcriptase polymerase chain
reaction (RT–PCR) method. In this method, the real quantitative
expression level of survivin mRNA cannot be estimated. To inves-
tigate whether survivin mRNA expression is a good indicator of
cancer recurrence in OSCC, we used real-time RT–PCR method
that enabled the real quantitative expression levels of survivin
mRNA in each OSCCs to be evaluated.
MATERIALS AND METHODS
Cell line
The human OSCC cell line EC-GI-10 was purchased from Riken
Gene Bank (Tsukuba Science City, Japan). EC-GI-10 was main-
tained in Dulbecco’s modiﬁed Eagle’s medium (GIBCO BRL,
Grand Island, NY, USA) containing 10% foetal calf serum (GIBCO
BRL) and 1% penicillin/streptomycin (GIBCO BRL) in a humidi-
ﬁed atmosphere containing 5% CO2 at 378C.
Tissues
We obtained tumours and adjacent non-cancerous oesophageal
epithelium samples from 57 patients with OSCC who underwent
oesophagectomy between 1993 and 2000. Informed consent was
obtained from all patients for subsequent use of their resected
tissues. The present study conformed to the ethical standards of
the World Medical Association Declaration of Helsinki. Tissue
samples of approximately 0.1 g were collected immediately after
resection of specimen. Non-cancerous tissues were obtained from
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www.bjcancer.comregions distant from the tumours. Half of each tissue sample was
ﬁxed in 10% buffered formalin and embedded in parafﬁn. Sections
(4 mm thick) were prepared for hematoxylin-eosin staining for
histopathologic diagnosis and for immunohistochemical staining.
The other half of the tissue was stored at 7808C until needed.
Patients
The subjects (57 OSCC patients) included 54 men and three
women, age at time of surgery was 65.2+1.2 years (mean+stan-
dard error; median, 67; range 45–84). Tumours were staged
according to the TNM system. The stages of the 57 patients were
Stage I (n=8), II (n=18), III (n=26), and IV (n=5). None of the
patients received preoperative chemotherapy or radiation therapy.
Transthoracic oesophagectomy was performed on 36 patients by
right-sided antero-lateral thoracotomy and laparotomy. Intrathor-
acic and perigastric lymph nodes were dissected during this
procedure. Transhiatal oesophagectomy without thoracotomy was
performed on 19 patients. Lower oesophagectomy through the
transabdominal approach was performed on two patients. Curative
oesophagectomy was performed on 45 patients and non-curative
oesophagectomy was performed on 12 patients (one: liver metasta-
sis, three: extended lymph node metastasis, and eight: local
invasion). All patients were followed until February 2002. The
mean follow-up period for the 57 patients was 29.2 months
(ranging from 1–99 months). Causes of death were determined
from clinical ﬁndings. Nineteen patients were alive at February of
2002, and a total of 38 patients had died. Six patients died from
diseases other than OSCC (four died from operative complications
and the in-hospital mortality rate was 7%), while 32 died from
recurrence or relapse of OSCC.
Detection of survivin transcripts using real-time RT–PCR
Before starting the study, histopathologic examination conﬁrmed
that there were a sufﬁcient number of cancer cells in the tumour
samples and that no cancer cells had contaminated the non-cancer-
ous tissues. Total RNA from EC-GI-10 and tissues was isolated
using RNeasy Mini Kits (Qiagen, Hilden, Germany) according to
the manufacturer’s protocol. Total RNA was eluted with 50 mlo f
diethylpyrocarbonate (DEPC) water. RNA concentrations were
determined by spectrophotometry. One microgram of the total
RNA from each sample was heated to 608C in a water bath for
10 min then cooled on ice for 2 min. Complementary DNA
(cDNA) was synthesised with 1 mg of total RNA and 0.5 mg oligo
(dT)15 primer (Promega, Madison, WI, USA) with Ready-to-Go
TM
You-Prime First-Strand Beads (Amersham Pharmacia Biotech Inc.,
Piscataway, NJ, USA). The beads contained moloney murine
leukaemia virus reverse transcriptase (M-MuLV RT), 50 mM
Tris-HCl (pH 8.3), 75 mM KCl, 7.5 mM DTT, 10 mM MgCl2,
and 2.4 mM of each dNTP. Total volume was adjusted to 50 ml
with DEPC water. The beads with the reaction mixture were incu-
bated at 378C for 60 min.
Primers and the TaqMan probes for survivin and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH)( survivin: forward primer; 5'-
TGCCCCGACGTTGCC-3', reverse primer; 5'-CAGTTCTTGAATG-
TAGAGATGCGGT-3', and probe; 5'-CCTGGCAGCCCTTTCTCA-
AGGACC-3', GAPDH: forward primer; 5'-GAAGGTGAAGGTCG-
GAGTC-3', reverse primer; 5'-GAAGATGGTGATGGGATTTC-3',
and probe; 5'-CAAGCTTCCCGTTCTCAGCC-3') were synthesised
according to a previous report (Wen et al, 2000). Speciﬁc oligonu-
cleotide probes were labelled with a reporter ﬂuorescent dye (FAM
(6-carboxy-ﬂuorescein)) at the 5' end and a quencher ﬂuorescent
dye (TAMRA (6-carboxy-tetramethyl-rhodamine)) at the 3' end.
AmpliTaq DNA polymerase extended the primer and displaced
the TaqMan probe through its 5'–3' exonuclease activity. No
signal was emitted when the probe was intact.
Quantiﬁcation of gene expression
Quantiﬁcation of gene expression was performed by real-time
quantitative RT–PCR (Gene Amp
1 5700 Sequence Detection
System (Perkin-Elmer Applied Biosystems, Foster City, CA,
USA)), which uses the 5' nuclease activity of Taq polymerase to
detect PCR amplicons (Yajima et al, 1998; Mitas et al, 2001).
The PCR solution (50 ml) was composed of 1 ml of cDNA solution,
5 pmol of the forward and reverse primers, 10 pmol of internal
probe, and TaqMan Universal PCR Master Mix. PCR was carried
out after incubation at 508C for 2 min, denaturing at 958C for
10 min, 45 cycles of 958C for 15 s, and 618C for 1 min. Experi-
ments were performed in duplicate for each data point. For each
reaction tube, the ﬂuorescence signal of the reporter dye (FAM)
was divided by the ﬂuorescence signal of the passive reference
dye (TAMRA) to obtain a ratio deﬁned as the normalised reporter
signal (Rn). The threshold line was set at an Rn of 0.05 (10 stan-
dard deviations above the mean of the baseline ﬂuorescence
emission calculated from cycles 3–20) (Yajima et al, 1998). The
point at which the ampliﬁcation plot crossed this threshold was
deﬁned as Ct, which represented the cycle number at this point.
Standard curves for survivin, and GAPDH were generated using
serial dilution (containing 160, 80, 40, 20 and 10 ng) of total
RNA derived from the EC-GI-10 cell line. The plots represent
the log of the input amount (log ng of total starting RNA) as
the x-axis and Ct as the y-axis. Equations were derived from the
lines of the calibration curves (Yajima et al, 1998). The formulas
for survivin and GAPDH were as follows: survivin, y=28.6–3.6x
(r
2=0.998) and GAPDH, y=26.3–4.5x (r
2=0.991) (Figure 1). For
each of the experimental samples, the amount of survivin and
GAPDH mRNAs were determined from the standard curves.
GAPDH transcripts were monitored as a control to quantify the
transcripts of the genes in each sample. The normalised amounts
of survivin mRNA, respectively, were determined by dividing the
amount of survivin mRNA by the amount of GAPDH mRNA for
each sample.
Immunohistochemistry
To identify survivin protein expressing cells, tissue samples
(tumours and non-cancerous oesophageal epitheliums) were
immunostained with a rabbit anti-human survivin polyclonal anti-
body (diluted to 1:20; Alpha Diagnostic International, San
Antonio, TX, USA). After overnight incubation the slides with a
primary antibody at 48C, ENVISION+ (DAKO Japan Co. Ltd.,
Kyoto, Japan) was applied as the secondary antibody for 30 min.
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Figure 1 Standard curves for survivin and GAPDH. The plots represent
the log of the input amount (log ng of total starting RNA of EC-GI-10; a:
160 ng, b: 80 ng, c: 40 ng, d: 20 ng, e: 10 ng) as the x-axis and threshold
cycle (Ct) as the y-axis for survivin and GAPDH.
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the chromogen, and the slides were counterstained with methyl
green.
Statistical analysis
The w
2 and Fishers exact probability tests were used to compare the
distribution of individual variables among the patient groups.
Differences in the numerical data between the two groups were
evaluated using the Mann-Whitney U test. Differences in the
numerical data among more than three groups were evaluated
using the Kruskal–Wallis test. Survival rates were calculated using
the Kaplan–Meier method. The log rank test was used for compar-
isons of two survival curves. The inﬂuence of each variable on
mode of recurrence was assessed by the multivariate logistic regres-
sion analysis. A P-value of 0.05 was considered to be statistically
signiﬁcant.
RESULTS
Survivin/GAPDH ratio in tumours and in non-cancerous
tissue of the oesophagus
The survivin/GAPDH ratio of carcinomas (mean+standard error
(s.e.): 5.3+0.8, range: 0.4–37) was signiﬁcantly higher than that
of non-cancerous tissues (3.6+0.8, range: 0–37.5, P=0.0003).
Figure 2 shows one typical case. In this case, the survivin/GAPDH
ratio of the tumour tissue was 3-fold higher than that of non-
cancerous tissue. A signiﬁcant positive correlation between
tumour-survivin/GAPDH ratios and non-cancerous tissue-survi-
vin/GAPDH ratios was detected in 57 patients (r=0.413,
P=0.0022). However, the survivin/GAPDH ratio of tumours did
not correlate with histologic type, lymph node involvement, or
depth of tumour invasion (Table 1).
Localisation of survivin protein in oesophageal tissue
Survivin protein was detected not only in the cytoplasm, but also
in nuclei of all cancer cells (Figure 3) and normal basal cells in
non-cancerous epithelium. Normal basal cells showed weak survi-
vin protein expression (Figure 4). Sixteen tumours expressed
strong survivin protein, while the remaining 41 tumours expressed
weak survivin protein as same level as normal basal cells. The survi-
vin/GAPDH ratio of 16 tumours with strong survivin protein
expression (11.5+2.1) was signiﬁcantly higher than that of 41
tumours with weak expression (2.9+0.3, P50.0001).
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Figure 2 Ampliﬁcation curves of survivin and GAPDH in a typical case.
Line a: GAPDH of tumour, line b: GAPDH of non-cancerous tissue adjacent
to carcinoma, line c: survivin of tumour, and line d: survivin of non-cancerous
tissue. The horizontal line at Rn=0.05 is the threshold for detection.
Figure 3 Strong survivin protein expression was detected in nuclei of all
cancer cells and weak survivin expression was observed in the cytoplasm by
immunostaining with a polyclonal antibody (6100).
Figure 4 Normal esophageal cells in the basal layer show weak survivin
protein expression (6100).
Table 1 Clinicopathological ﬁndings of patients and tumor-survivin/
GAPDH mRNA ratios
Tumor-survivin/GAPDH
mRNA ratio
N (mean+s.e.) P
Histologic type of tumour
Well differentiated 2 9.2+8.3
Moderately differentiated 29 4.8+0.9 0.6655
Poorly differentiated 26 5.6+1.4
Lymph node metastasis
Negative 22 4+0.8 0.2828
Positive 35 6.2+1.2
Invasion to adventitia
Negative 22 5.2+0.9 0.5066
Positive 35 5.4+1.2
s.e.: standard error.
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OSCC
We divided the 57 patients into two subgroups according to their
tumour-survivin/GAPDH ratio. The cut-off value of the survivin/
GAPDH ratio of tumours was decided from the formula
(mean+26s.e.) of 57 non-cancerous tissue-survivin/GAPDH ratios
(Cheung and Cheung, 2001). Mean survivin/GAPDH ratio of 57
non-cancerous tissues was 3.6 and s.e. was 0.8. Thus, the calculated
cut-off value of survivin/GAPDH ratio of tumours was 5.2. Eigh-
teen tumours showed high survivin/GAPDH ratio (45.2) and 13
of these 18 (72%) showed strong survivin protein expression by
immunohistochemistry. While in 39 tumours with low survivin/
GAPDH ratio (45.2), only three tumours (7.7%) showed strong
protein expression. Figure 5 shows the survival curves of the 53
surviving patients. The survival curve of 17 patients with high-
survivin/GAPDH ratio-tumours (45.2, 5-year survival rate was
14.1%) was signiﬁcantly lower than that of 36 patients with low-
survivin/GAPDH ratio-tumours (45.2, 5-year survival rate was
46.8%, P=0.0018). In February 2002, in the 53 surviving patients,
tumour recurrence or relapse was detected in 33 (62.3%) and 32
had died from OSCC. The mean tumour-survivin/GAPDH ratio
of the 33 who had developed recurrent or relapsed tumours
(6.3+1.2) was higher than that of the 20 without tumour recur-
rence or relapse (3.6+0.7, P=0.0281). The clinicopathological
and the biological factors, thought to be correlated with the occur-
rence of cancer recurrence, were analysed. By multivariate logistic
regression analysis, the tumour-survivin/GAPDH ratio was detected
as a risk factor of cancer recurrence independent from depth of
tumour invasion or lymph node involvement (Table 2).
In the 53 surviving patients, adjuvant radiation therapy was
performed for 36 patients (total dose was 30 to 50 Grays). The
remaining 17 patients were excluded from adjuvant radiation ther-
apy because of high age, cardio-pulmonary complication, or early
stage of tumour. The 5-year survival rate of the 36 patients who
underwent adjuvant radiation therapy (32.8%) was not different
from that of the 17 patients who did not (45.8%, P=0.3317).
The 5-year survival rates of patients with high-tumour-survivin/
GAPDH ratio (with adjuvant therapy, n=8, 0%; without adjuvant
therapy, n=9, 22.2%) were signiﬁcantly poorer than those of
patients with low-tumour-survivin/GAPDH ratio (with adjuvant
therapy, n=28, 40.1%, P=0.0014; without adjuvant therapy, n=8,
72.9%, P=0.0253).
DISCUSSION
The role of survivin protein is unique, having been shown to bind
speciﬁcally to caspases-3 and -7 and to inhibit apoptosis in vitro
system (Tamm et al, 1998). Furthermore, Li et al (1998) reported
that survivin expresses during the G2/M phase of the cell cycle and
the disruption of survivin-microtubule interactions results in
increased caspase-3 activity and accelerated apoptotic cell death.
Ito et al (2000) reported that hepatocellular carcinoma cell lines
transfected with survivin show a signiﬁcant decrease in cells in
the G0/G1 phase and an increase in cells in the S and G2M phases.
These ﬁndings indicate that survivin protein expression may corre-
late not only with reduced apoptotic cell death but also with an
increased proliferative activity of cancer cells. Recently, the clinical
importance of survivin mRNA expression has been reported in
various cancers. These reports demonstrated that the prognosis
of patients with survivin mRNA expression positive tumours was
signiﬁcantly worse than that of patients with survivin negative.
The reports noted above were based on the RT–PCR method,
while in the present study we used real-time RT–PCR to evaluate
the quantitative expression levels of survivin mRNA in oesophageal
tissues instead of either the RT–PCR or Northern blot methods.
The expression levels of GAPDH (internal control) mRNA were
reported to be quite different among samples, even when the same
amounts of total RNAs were used (Suzuki et al, 2001). This
phenomenon might be overlooked in Northern blot or RT–PCR
assay. Moreover, Northern blot requires many complicated techni-
ques such as gel electrophoresis, membrane transfer, and
hybridisation and requires a comparatively long time to obtain
results. Also, it is difﬁcult to estimate the real amount of gene
expression level by a RT–PCR method. The recent development
of real-time RT–PCR technology has made reliable and accurate
PCR quantiﬁcation possible. This technology monitors the entire
PCR reaction by ﬂuorescence detection, thereby allowing the begin-
ning of the exponential phase of ampliﬁcation (threshold cycle) to
be measured. This reaction point is considered the most reliable
point of the PCR reaction relative to sample concentration
(Wittwer et al, 1997).
Using real-time RT–PCR method, we found that the mean
survivin mRNA expression level of non-cancerous oesophageal
tissues (the normalised amounts of survivin mRNA were deter-
mined by dividing the amounts of mRNA levels by the amount
of GAPDH mRNA for each sample) was 3.6. Kato et al (2001)
reported that survivin mRNA expression of normal oesophageal
tissues detected by RT–PCR method was observed in 47.1% of
cases and that this rate was higher than that of normal lung tissues
(12%) or that of normal colorectal tissues (29.1%). It is well
known that esophageal epithelium has rapid renewal (Takubo et
al, 1997). These ﬁndings indicate that survivin mRNA may express
with high proliferative activity even in normal tissues.
Our results demonstrated that tumour-survivin mRNA expres-
sion level did not correlate with lymph node metastasis or depth
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Figure 5 The disease-speciﬁc survival curves of the 53 surviving patients.
The survival curve of 17 with high-survivin/GAPDH ratio-tumours (line b)
was signiﬁcantly lower than that of 36 with low-survivin/GAPDH ratio-
tumors (line a). The difference between two survival curves was statistically
signiﬁcant (P=0.0018).
Table 2 Factors affecting tumour recurrence analysed by multivariate
logistic regression analysis
Variable w
2 P
Invasion to adventitia 5.007 0.0253
(Positive vs Negative)
Lymph node metastasis 3.518 0.0607
(Positive vs Negative)
Post-operative radiation therapy 0.082 0.7739
(Yes vs No)
Tumour-survivin mRNA expression 6.154 0.0131
(High vs Low)
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colorectal carcinoma (Sarela et al, 2000) and in non-small-cell lung
cancer (Monzo ￿ et al, 1999). These ﬁndings indicate that tumour-
survivin mRNA expression level may not correlate with metastatic
potential of tumour cells.
However, in previous studies, and in ours, patients who had
tumours with high survivin mRNA expression revealed shorter
survival. Recently, it has been shown that pancreatic cancer cells
or gastric cancer cells with strong survivin mRNA expression
showed a chemo-radioresistance in vitro (Asanuma et al, 2000;
Ikeguchi et al, 2002). Moreover, from a clinical perspective,
patients with survivin mRNA positive tumours showed chemo-
radioresistance in OSCC (Kato et al, 2001). In a study of neuro-
blastoma (Azuhata et al, 2001), and in our study of OSCC,
tumour-survivin mRNA expression showed strong positive correla-
tions with the tumour recurrence of patients. From these results, it
is suggested that micrometastatic foci with strong survivin mRNA
expression may have high proliferative activity and may increase
rapidly and also may acquire resistance to adjuvant chemo-radio-
therapy.
We conclude that survivin mRNA expression may become a
useful prognostic biomarker in OSCC and the quantitative real-
time RT–PCR method is a useful technique for determining gene
expression levels in tissue.
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